Skip to content

Study · Not a test of the peptide alone · 2015

5 results

Ulinastatin- and thymosin α1-based immunomodulatory strategy for sepsis: A meta-analysis.

Han D, Shang W, Wang G, Sun L, Zhang Y, Wen H, Xu L

International immunopharmacology27 Oct 2015Cited by 23 (Europe PMC)

PMID26522590 (opens in a new tab)DOI10.1016/j.intimp.2015.10.026 (opens in a new tab)PepBankPUB-26522590
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In patients with sepsis, ulinastatin combined with thymosin α1 lowered 28-day all-cause mortality compared with placebo in a meta-analysis (RR 0.67).

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 lowered 28-day deaths compared with placebo in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    Decrease28-day all-cause mortality
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Mortality · Infection

    Measurements

    RR
    0.67
    28-day all-cause mortality

    Source sentences

    Summary
    Compared with placebo, the combination of ulinastatin and Tα1 presented significant effects on 28-day all-cause mortality (RR 0.67; 95% CI 0.57 to 0.80)
    2 context sentences
    Summary · context
    Randomized clinical trials on treatment of sepsis with the combination of ulinastatin and Tα1, compared with placebo, were reviewed.
    Summary · context
    Six trials (enrolling 915 participants) met the inclusion criteria.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In patients with sepsis, ulinastatin combined with thymosin α1 lowered 90-day all-cause mortality compared with placebo in a meta-analysis (RR 0.75).

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 lowered 90-day deaths compared with placebo in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    Decrease90-day all-cause mortality
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Mortality · Infection

    Measurements

    RR
    0.75
    90-day all-cause mortality

    Source sentences

    Summary
    90-day all-cause mortality (RR 0.75; 95% CI 0.61 to 0.93)
    3 context sentences
    Summary · context
    Compared with placebo, the combination of ulinastatin and Tα1 presented significant effects on
    Summary · context
    Randomized clinical trials on treatment of sepsis with the combination of ulinastatin and Tα1, compared with placebo, were reviewed.
    Summary · context
    Six trials (enrolling 915 participants) met the inclusion criteria.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In patients with sepsis, ulinastatin combined with thymosin α1 lowered TNF-α compared with placebo in a meta-analysis (WMD -73.86ng/L).

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 lowered TNF-α compared with placebo in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTNF-α level
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation

    Measurements

    WMD
    −73.86 ng/L
    TNF-α

    Source sentences

    Summary
    TNF-α (WMD -73.86ng/L; 95% CI -91.00 to -56.73ng/L)
    3 context sentences
    Summary · context
    Compared with placebo, the combination of ulinastatin and Tα1 presented significant effects on
    Summary · context
    Randomized clinical trials on treatment of sepsis with the combination of ulinastatin and Tα1, compared with placebo, were reviewed.
    Summary · context
    Six trials (enrolling 915 participants) met the inclusion criteria.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In patients with sepsis, ulinastatin combined with thymosin α1 lowered IL-6 compared with placebo in a meta-analysis (WMD -55.04ng/L).

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 lowered IL-6 compared with placebo in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-6 level
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation

    Measurements

    WMD
    −55.04 ng/L
    IL-6

    Source sentences

    Summary
    IL-6 (WMD -55.04ng/L; 95% CI -61.22 to -48.85ng/L)
    3 context sentences
    Summary · context
    Compared with placebo, the combination of ulinastatin and Tα1 presented significant effects on
    Summary · context
    Randomized clinical trials on treatment of sepsis with the combination of ulinastatin and Tα1, compared with placebo, were reviewed.
    Summary · context
    Six trials (enrolling 915 participants) met the inclusion criteria.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In patients with sepsis, ulinastatin combined with thymosin α1 shortened mechanical ventilation compared with placebo in a meta-analysis (WMD -2.26 days).

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 shortened ventilator time compared with placebo in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseDuration of mechanical ventilation
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Respiratory

    Measurements

    WMD
    −2.26 days
    duration of mechanical ventilation

    Source sentences

    Summary
    duration of mechanical ventilation (WMD -2.26days; 95% CI -2.79 to -1.73days).
    3 context sentences
    Summary · context
    Compared with placebo, the combination of ulinastatin and Tα1 presented significant effects on
    Summary · context
    Randomized clinical trials on treatment of sepsis with the combination of ulinastatin and Tα1, compared with placebo, were reviewed.
    Summary · context
    Six trials (enrolling 915 participants) met the inclusion criteria.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.